---
layout: post
title: "Chronic Rhinosinusitis With Nasal Polyps: Developing Drugs for Treatment; Guidance for Industry; Availability"
date: 2026-02-05 18:56:01 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-13884
original_published: 2023-06-30 00:00:00 +0000
significance: 8.00
---

# Chronic Rhinosinusitis With Nasal Polyps: Developing Drugs for Treatment; Guidance for Industry; Availability

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** June 30, 2023 00:00 UTC
**Document Number:** 2023-13884

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Chronic Rhinosinusitis With Nasal Polyps: Developing Drugs for Treatment." The purpose of this guidance is to assist sponsors in the development of drugs or biological products for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). Specifically, this guidance addresses FDA's current thinking regarding trial population and design, effectiveness, statistical analysis, and safety for drugs being developed for the treatment of CRSwNP. This guidance finalizes the draft guidance of the same title issued on December 10, 2021.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/06/30/2023-13884/chronic-rhinosinusitis-with-nasal-polyps-developing-drugs-for-treatment-guidance-for-industry)
- API: https://www.federalregister.gov/api/v1/documents/2023-13884

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
